HC Wainwright & Co. analyst Andrew S. Fein maintains BioCryst Pharma (NASDAQ:BCRX) with a Buy

Wall Street analysts changed outlook on top names. Wedbush raised Replimune's price target, Cana

Cantor Fitzgerald analyst Steven Seedhouse maintains BioCryst Pharma (NASDAQ:BCRX) with a Overwei

BioCryst Pharmaceuticals said on Monday it would wind down its internal drug discovery programs and

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) ("BioCryst" or the "Company") today ann

—Advances strategic shift toward a disciplined research model prioritizing external innovation to ac

BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will present seven ab

Studies highlight the significant healthcare and quality-of-life burden associated with hereditary a

BioCryst Pharma (NASDAQ:BCRX) reported strong Q1 earnings, reaffirmed FY2026 sales guidance, and rec

Citizens analyst Jonathan Wolleben maintains BioCryst Pharma (NASDAQ:BCRX) with a Market Outperfo

Wedbush analyst Laura Chico maintains BioCryst Pharma (NASDAQ:BCRX) with a Outperform and lowers

Needham analyst Serge Belanger maintains BioCryst Pharma (NASDAQ:BCRX) with a Buy and lowers the

BioCryst Pharma (NASDAQ:BCRX) affirms FY2026 sales outlook from $635.000 million-$660.000 million to

BioCryst Pharma (NASDAQ:BCRX) reported quarterly earnings of $0.14 per share which beat the analyst

— BioCryst grants Irish affiliate of Neopharmed Gentili exclusive license to commercialize navenibar

PAVS stock rose 65.6% in pre-market trading after ending sales agreement with A.G.P/Alliance Global

BioCryst Pharma (NASDAQ:BCRX) affirms FY2026 sales outlook from $635.000 million-$660.000 million to

BioCryst Pharma (NASDAQ:BCRX) reported quarterly earnings of $0.06 per share which beat the analyst

BioCryst Pharma (NASDAQ:BCRX) reported quarterly sales of $163.284 million which beat the analyst co

BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will present nine abs

RBC Capital analyst Brian Abrahams maintains BioCryst Pharma (NASDAQ:BCRX) with a Outperform and

BioCryst Pharma (NASDAQ:BCRX) sees FY2026 sales of $635.000 million-$660.000 million vs $657.200 mil

HC Wainwright & Co. analyst Andrew S. Fein maintains BioCryst Pharma (NASDAQ:BCRX) with a Buy

BioCryst secures FDA approval for Orladeyo oral pellets, expanding preventive HAE therapy to childre

–ORLADEYO now first and only targeted oral prophylactic therapy for patients with HAE aged 2 and old

 Findings highlight negative psychosocial impact of HAE attacks and resulting ED/hospital visits on

Citizens analyst Jonathan Wolleben maintains BioCryst Pharma (NASDAQ:BCRX) with a Market Outperfo

Barclays analyst Gena Wang maintains BioCryst Pharma (NASDAQ:BCRX) with a Equal-Weight and lowers

Needham analyst Serge Belanger maintains BioCryst Pharma (NASDAQ:BCRX) with a Buy and lowers the

Retail investors are preparing for another busy week of earnings season with more than 1,600 compani

BioCryst Pharma (NASDAQ:BCRX) raises FY2025 sales outlook from $580.000 million-$600.000 million to

BioCryst Pharma (NASDAQ:BCRX) reported quarterly earnings of $0.16 per share which beat the analyst

BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will present four abs

Cantor Fitzgerald analyst Steven Seedhouse maintains BioCryst Pharma (NASDAQ:BCRX) with a Overwei

JMP Securities analyst Jonathan Wolleben maintains BioCryst Pharma (NASDAQ:BCRX) with a Market Ou

Needham analyst Serge Belanger maintains BioCryst Pharma (NASDAQ:BCRX) with a Buy and raises the

BioCryst will acquire Astria Therapeutics for $700 million to expand its HAE portfolio with naveniba

FDA approved Ionis' Dawnzera for hereditary angioedema, showing up to 87% attack reduction and s